{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-25-000028","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.087318+00:00","generated_at":"2026-05-26T04:56:28.324188+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment","bullets":["Earnings release and call postponed; 10-K filing delayed until March 18, 2025.","Preliminary FY2024 revenue near midpoint of $255M-$265M guidance.","Additional time needed for goodwill impairment assessment related to Alphazyme LLC acquisition.","Revenue recognition error for ~$3.9M shipment recorded in wrong quarter; no full-year impact.","Assessing effectiveness of internal controls; material weakness in revenue recognition identified."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-25-000028","json":"https://secwatch.observer/filing/0001823239-25-000028.json","markdown":"https://secwatch.observer/filing/0001823239-25-000028.md","text":"https://secwatch.observer/filing/0001823239-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/0001823239-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000028/mrvi-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:56:28.324188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}